Adaptive designs within ongoing Phase II-III clinical trials on candidate therapeutics may shorten trial durations and use fewer subjects, possibly expediting decisions for early termination or success, and coordinating design changes for a specific trial across its international locations.
نەک تەنها ئەوە، بەڵام کاتێک لەو وڵاتانەوە هاتوونTico19 Tico19